Plain-English translation of NCT03907046 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a blood thinner called works better than for people who have survived a brain bleed (intracerebral hemorrhage) and also have a condition called atrial fibrillation, which causes irregular heartbeats. After a brain bleed, doctors face a difficult choice: patients need protection against future strokes, but blood thinners can increase the risk of another bleed. This study will help doctors understand which treatment is safest and most effective.
People who have had a brain bleed and irregular heartbeats are at risk for future strokes, but doctors aren't sure whether to use blood thinners or to protect them. This medication could offer better protection against strokes while keeping the brain safer, but we need to test this carefully in a large group of patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the medication (in two doses per day) or (once per day) for at least 12 months and up to 36 months. You'll visit the study site regularly for check-ups, blood tests, and follow-up assessments to see how you're recovering and whether you have any side effects. Researchers will track whether you have any new strokes or other health events during the study.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States